Lilly Announces an Extension to 2015 Research Collaboration deal with Dana Farber Cancer Institute
Shots:
- The extension provides a better understanding to clinicians and initial funding discoveries- molecular analyses- design and conduct of samples for new discoveries in cancer
- Agreement defines that Dana has right to perform multiple clinical and preclinical trials adding in Lilly’s pipeline
- Evaluated compound ownership will remain under Lilly
Ref: Lilly | Image: Lilly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com